% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • beavertail_splash beavertail_splash Dec 21, 2007 9:09 PM Flag

    Unloved Siga about to be loved and

    I think someone already responded with this same argument Dip to the surgeon's time line earlier today! No doubt some large institution bailed last minute bfr tax year ends. surprised it only dropped by 11 cents with so much selling or buying?
    It will be a lean Christmas for Siga holders.....we'll just be exchanging glances this Christmas, I guess. The new year looks more promising!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • from PPD for drug development:
      Phase I Clinical Studies. Phase I studies are designed to verify safety and tolerability of the candidate drug in humans and typically take six to nine months. These are the first studies conducted in humans. A small number of subjects, usually from 20 to 100 healthy volunteers, take the investigational drug for short periods of time. Testing includes observation and careful documentation of how the drug acts in the body -- how it is absorbed, distributed, metabolized and excreted.
      Phase II Clinical Studies. Phase II studies are designed to determine effectiveness and further study the safety of the candidate drug in humans. Depending upon the type of investigational drug and the condition it treats, this phase of development generally takes from six months up to three years. Testing is conducted with up to several hundred patients SUFFERING FROM THE CONDITION the investigational drug is designed to treat. THIS CANNOT TAKE PLACE WITH SMALLPOX. This testing determines safety and effectiveness of the drug in treating the condition and establishes the minimum and maximum effective dose. Most Phase II clinical trials are randomized, or randomly divided into groups, one of which receives the investigational drug, one of which gets a placebo containing no medication and sometimes a third that receives a current standard treatment to which the new investigational drug will be compared. In addition, most Phase II studies are double-blinded, meaning that neither patients nor researchers evaluating the compound know who is receiving the investigational drug or placebo. THEREFORE ST-246 WILL NOT BE SUBJECTED TO PHASE 11 STUDIES!

0.94+0.0300(+3.30%)May 5 11:33 AMEDT